PET/CT Scans Predict Biliary Cancer Therapy Response | CHA Bundang Hospital
New research suggests that detailed metabolic information obtained from , FDG PET/CT scans can provide valuable insights into predicting outcomes for patients with advanced biliary tract cancers (BTC). This finding has the potential to refine treatment strategies and improve prognosis assessment for a disease that often presents a significant clinical challenge.
Understanding Biliary Tract Cancer
Biliary tract cancers are a group of malignancies affecting the bile ducts – the tubes that carry digestive fluid from the liver to the small intestine. These cancers can develop in different locations: inside the liver (intrahepatic), in the ducts outside the liver (extrahepatic), or in the gallbladder. BTCs are frequently diagnosed at a late stage, which complicates treatment and contributes to a poorer prognosis.
Standard treatment for BTC typically involves surgery, when feasible, combined with chemotherapy and radiation therapy. However, advancements in precision medicine and genetics offer promise for more targeted approaches.
The Role of FDG PET/CT Scans
Positron emission tomography/computed tomography (PET/CT) scans using 18F-fluorodeoxyglucose (18F-FDG) are commonly used in the staging and monitoring of various cancers, including BTC. These scans detect areas of increased metabolic activity, which can indicate the presence of cancerous cells. The scans provide both anatomical information (from the CT component) and functional information (from the PET component), offering a comprehensive view of the disease.
Traditionally, the interpretation of FDG PET/CT scans in BTC has focused on identifying the primary tumor and any distant metastases. However, recent studies are highlighting the potential of analyzing specific metabolic parameters derived from these scans to predict how patients will respond to therapy and their overall prognosis.
New Insights from Metabolic Indicators
A meta-analysis published in January 2024 demonstrates the potential of analyzing specific metabolic parameters derived from FDG PET/CT scans to predict patient response to therapy and overall prognosis. These metabolic indicators can help refine staging and identify patients who may benefit most from aggressive treatment approaches, such as surgery or chemotherapy. The scans can also be used to monitor treatment response, allowing clinicians to adjust therapy as needed.
Beyond FDG PET/CT: The Emerging Role of FAPI PET/CT
While FDG PET/CT has proven valuable, a newer imaging technique, FAPI PET/CT, is gaining attention for its potential advantages in diagnosing and staging cholangiocarcinoma and pancreatic cancer. Fibroblast activation protein alpha (FAP) is a molecular target that shows promise, particularly in tumors with a pronounced desmoplastic reaction – a dense, fibrous tissue surrounding the tumor.
Radiolabeled FAP inhibitors (FAPIs) enable noninvasive visualization of cancer using PET/CT. Recent studies have demonstrated that FAPI PET/CT provides superior sensitivity compared to traditional contrast-enhanced CT (ceCT) and 18F-FDG PET/CT in detecting primary tumors, lymph node involvement, and distant metastases, particularly in the liver. This improved sensitivity can affect TNM staging and subsequently alter treatment-decision making.
Prognostic Potential and Limitations
Beyond staging, early evidence suggests that FAPI PET/CT may have prognostic potential in tumor grading, therapy response assessment, and predicting survival outcomes, although more data are needed to confirm these findings. The scans can also help predict biliary tract cancer grade and therapy response.
However, it’s important to acknowledge the limitations of FAPI PET/CT. False-positive findings can occur in the context of fibrotic and inflammatory processes, such as liver cirrhosis, pancreatitis, or primary sclerosing cholangitis. In other words that careful interpretation of the scans is crucial, and clinical context must always be considered.
Looking Ahead
Recent advancements in radiomics, biomarkers, and optimal biliary decompression are providing new opportunities to improve outcomes for patients with cholangiocarcinoma. These innovations are reshaping the understanding and management of this complex disease, offering noninvasive diagnostic tools, enhanced prognostic capabilities, and improved therapeutic strategies. While challenges remain, the continued development and refinement of imaging techniques like FDG PET/CT and FAPI PET/CT offer hope for improved diagnosis, treatment, and better outcomes for individuals battling biliary tract cancers.